Objective  To observe the clinical efficacy of omadacycline in treating elderly patients with chronic obstructive pulmonary disease(COPD) complicated by community-acquired bacterial pneumonia (CABP).

Methods  The clinical data of elderly patients with COPD and CABP treated in Shaoxing Municipal Hospital from June 2023 to December 2024 were retrospectively analyzed. According to the different treatment drugs, they were divided into an observation group (omadacycline treatment) and a control group (other first-line drug treatment), and the clinical data of the two groups of patients were compared.

Results  A total of 100 patients were enrolled, with 39 in the observation group and 61 in the control group. Before treatment, there were no statistically significant differences in C-reactive protein (CRP), procalcitonin (PCT), white blood cell count (WBC), interleukin-6 (IL-6), forced vital capacity (FVC), forced expiratory volume in one second (FEV1), FEV1/FVC ratio, and the percentage that FEV1 accounts for in the predicted value between the two groups (P>0.05). After treatment, the observation group showed significantly lower levels of CRP, PCT, WBC, and IL-6 than the control group (P<0.05), and higher levels of FVC, FEV1, FEV1/FVC ratio, and the percentage that FEV1 accounts for in the predicted value (P<0.05). The observation group also had significantly shorter times for cough resolution, sputum resolution, fever resolution, lung rale resolution, dyspnea resolution, and hospital stay (P<0.05), and a significantly higher total effective rate (94.87% vs. 85.24%, P<0.05). After treatment, there were no statistically significant differences in adverse reactions between the two groups (P>0.05).

Conclusion  Omadacycline has certain clinical effects in the treatment of elderly patients with COPD and CABP with good safety.

1.朱丹, 陈燕, 双庆翠, 等. 慢性阻塞性肺疾病急性加重期与慢性阻塞性肺疾病合并社区获得性肺炎的临床观察性分析[J]. 结核与肺部疾病杂志, 2022, 3(2): 118-124. [Zhu  D, Chen Y, Shuang QC, et al. Clinical observation of patients with acute axcerbation of chronic obstructive pulmonary disease and patients with chronic obstructive pulmonary disease plus community-acquired pneumonia[J]. Journal of Tuberculosis and Lung Disease, 2022, 3(2): 118-124.] DOI: 10.19983/j.issn.2096-8493.20210166.

2.陈志博, 俞宁宁, 林圣乐. 吸入糖皮质激素对慢性阻塞性肺疾病合并社 区获得性肺炎预后影响的回顾性研究[J]. 中国药师, 2023, 26(11): 279-285. [Chen ZB, Yu NN, Lin SL. Retrospective study of effect of inhaled corticosteroids on prognosis of chronic obstructive pulmonary disease associated with community-acquired pneumonia[J]. China Pharmacist, 2023, 26(11): 279-285. ] DOI: 10.12173/j.issn.1008-049X.202311051.

3.夏静, 瞿香坤, 王其凯, 等. 疏风解毒胶囊联合哌拉西林他唑巴坦治疗慢性阻塞性肺疾病急性加重期合并社区获得性肺炎的临床观察[J]. 中国中医急症, 2021, 30(7): 1233-1236. [Xia J, Qu XK, Wang QK, et al. Clinical efficacy of Shufeng Jiedu capsules combined with piperacillin tazobatam in the treatment of AECOPD with CAP[J]. Journal of Emergency in Traditional Chinese Medicine, 2021, 30(7): 1233-1236.] DOI: 10.3969/j.issn.1004-745X.2021.07.027.

4.陈明毅, 唐可京, 陈杰. 奥马环素在特殊人群、特殊病理状态患者中应用研究进展[J]. 中国新药杂志, 2023, 32(22): 2300-2305. [Chen MY, Tang KJ, Chen J. Progress in research on application of omadacycline in special population and patients with special pathological status[J]. Chinese Journal of New Drugs, 2023, 32(22): 2300-2305.] DOI: 10.3969/j.issn.1003-3734.2023.22.012.

5.Sakoulas G, Michael N, Matthew G. Omadacycline in treating community-based infections: a review and expert perspective[J]. Expert Rev Anti Infect Ther, 2023, 21(3): 255-265. DOI: 10.1080/14787210.2023.2174100.

6.中华医学会呼吸病学分会慢性阻塞性肺疾病学组, 中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会. 慢性阻塞性肺疾病诊治指南（2021年修订版）[J]. 中华结核和呼吸杂志, 2021, 44(3): 170-205. [Chronic obstructive pulmonary disease group, respiratory branch, Chinese Medical Association, Working Committee on chronic obstructive pulmonary disease, respiratory branch, Chinese Medical Association. Guidelines for the diagnosis and management of chronic obstructive pulmonary disease (revised version 2021)[J]. Chinese Journal of Tuberculosis and Respiratory Diseases, 2021, 44(3): 170-205.] DOI: 10.3760/cma.j.cn112147-20210109-00031.

7.中华医学会呼吸病学分会. 中国成人社区获得性肺炎诊断和治疗指南（2016年版）[J]. 中华结核和呼吸杂志, 2016, 39(4): 253-279. [Chinese Thoracic Society (CTS). Guidelines for the diagnosis and treatment of community-acquired pneumonia in adults in China (2016 edition)[J]. Chinese Journal of Tuberculosis and Respiratory Diseases, 2016, 39(4): 253-279.] DOI: 10.3760/cma.j.issn.1001-0939.2016.04.005.

8.Corsaro B, Yang TY, Murphy R, et al. 2020 white paper on recent issues in bioanalysis: vaccine assay validation, qPCR assay validation, QC for CAR-T flow cytometry, NAb assay harmonization and ELISpot validation (part 3-recommendations on immunogenicity assay strategies, NAb assays, biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene & Cell therapy and vaccine assays)[J]. Bioanalysis, 2021, 13(6): 415-463. DOI: 10.4155/bio-2021-0007.

9.杨红霞, 揭凤英, 葛若星, 等. PCT、动脉血乳酸联合肺炎严重指数在重症社区获得性肺炎患者病情以及预后中的预测作用[J].分子诊断与治疗杂志, 2023, 15(10): 1774-1777. [Yang HX, Jie FY, Ge RX, et al. Correlation between the severity index of PCT and arterial blood lactate combined with pneumonia and the prognosis of patients with severe community-acquired pneumonia[J]. Journal of Molecular Diagnosis and Therapy, 2023, 15(10): 1774-1777.] DOI: 10.3969/j.issn.1674-6929.2023.10.028.

10.易琼, 李方, 雷思, 等. 自主研发的藏四味清肺合剂联合常规治疗对慢性阻塞性肺疾病急性加重期患者的临床疗效和安全性[J].中南大学学报（医学版）, 2024, 49(6): 921-931. [Yi Q, Li F, Lei S, et al. Clinical efficacy and safety of the self-developed Zangsiwei Qingfei mixture combined with conventional treatment in patients with acute exacerbation of chronic obstructive pulmonary disease[J]. Journal of Central South University (Medical Science), 2024, 49(6): 921-931.] DOI: 10.11817/j.issn.1672-7347.2024.230546.

11.王乐莹, 王义俊, 张莉. 奥马环素的抗菌活性、耐药性、药动学特性和临床疗效研究进展[J]. 中国药房, 2024, 35(20): 2571-2576. [Wang LY, Wang YJ, Zhang L. Research progress on antibacterial activity,resistance,pharmacokinetics characteristics and clinical efficacy of omadacycline[J]. China Pharmacy, 2024, 35(20): 2571-2576.] DOI: 10.6039/j.issn.1001-0408.2024.20.22.

12.Garey KW, Rose W, Gunter K, et al. Omadacycline and clostridioides difficile: a systematic review of preclinical and clinical evidence[J]. Ann Pharmacother, 2023, 57(2): 184-192. DOI: 10.1177/10600280221089007.

13.王玥坤, 高茗, 吴波, 等. 45例次奥马环素治疗的疗效及安全性初探[J]. 药学与临床研究, 2024, 32(6): 556-559. [Wang  YK, Gao M, Wu B, et al. A preliminary study on the efficacy and safety of omadacycline treat-ment in 45 cases[J]. Pharmaceutical and Clinical Research, 2024, 32(6): 556-559.] DOI: 10.13664/j.cnki.pcr.2024.06.021.

14.陈一帆, 侯周华, 胡琴, 等. 基于奥马环素治疗的临床疗效及影响因素分析[J]. 中国感染控制杂志, 2024, 23(9): 1106-1113. [Chen YF, Hou ZH, Hu Q, et al. Analysis on clinical efficacy and influencing factors based on omadacycline treatment[J]. Chinese Journal of Infection Control, 2024, 23(9): 1106-1113.] DOI: 10.12138/j.issn.1671-9638.20246447.

15.史海燕, 胡英, 黄建荣, 等. 奥马环素对比美罗培南联合利奈唑胺治疗肺部感染: 一项真实世界队列研究[J]. 中华临床感染病杂志, 2023, 16(3): 210-214. [Shi HY, Hu Y, Huang JR, et al. Comparison of omadacycline and meropenem plus linezolid in treatment of pulmonary infection: A real-world cohort study[J]. Chinese Journal of Clinical Infectious Diseases, 2023, 16(3): 210-214.] DOI: 10.3760/cma.j.issn.1674-2397.2023.03.008.

16.Ghali A, Morrisette T, Alosaimy S, et al. Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes[J]. Antimicrob Agents Chemother, 2023, 67(10): e0082423. DOI: 10.1128/aac.00824-23.

17.Huband MD, Fedler KA, Menders RE, et al. Surveillance of omadacycline against 35,000 bacterial clinical isolates from the United States (2019-2023)[J]. Diagn Microbiol Infect Dis, 2025, 111(3): 116711. DOI: 10.1016/j.diagmicrobio.2025.116711.

18.陈星如, 王导新. 单核细胞趋化因子-1联合C反应蛋白对慢性阻塞性肺疾病合并社区获得性肺炎的诊断价值研究 [J]. 中国实用内科杂志, 2021, 41(12): 1056-1060. [Chen XR, Wang  DX. Diagnostic value of monocyte chemokine-1 combined with C reactive protein in chronic obstructive pulmonary disease with community-acquired pneumonia[J]. Chinese Journal of Practical Internal Medicine, 2021, 41(12): 1056-1060.] DOI: 10.19538/j.nk2021120113.

19.赵莉婷, 夏菁, 梁家敏, 等. 奥马环素治疗2型糖尿病合并社区获得性细菌性肺炎的临床观察[J]. 中国药师, 2024, 27(5): 796-801. [Zhao LT, Xia J, Liang JM, et al. Clinical observation of omacycline in the treatment of type 2 diabetes mellitus complicated with community-acquired bacterial pneumonia[J]. China Pharmacist, 2024, 27(5): 796-801.] DOI: 10.12173/j.issn.1008-049X.202401150.

20.余如华, 徐蓉蓉, 吴书清. 奥马环素与莫西沙星治疗社区获得性肺炎的效果比较[J]. 中国医药导报, 2024, 21(17): 99-101. [Yu RH, Xu RR, Wu SQ. Comparison of the effects of Omadacycline and Moxifloxacin in the treat-ment of community-acquired pneumonia[J]. China Medical Herald, 2024, 21(17): 99-101.] DOI: 10.20047/j.issn1673-7210.2024.17.29.

21.王一凡, 肖卫. 血清CD71, ACTA水平对老年COPD合并肺部感染早期诊断价值研究[J]. 中国病原生物学, 2025, 20(1): 29-33. [Wang YF, Xiao W. The early diagnostic value of serum CD71 and ACTA levels for elderly COPD complicated with pulmonary infection[J]. Journal of Parasitic Biology, 2025, 20(1): 29-33.] DOI: 10.13350/j.cjpd.250106.

22.周霞, 娄丽丽, 杨柳, 等. 沙美特罗替卡松联合噻托溴铵治疗稳定期老年COPD患者的临床研究[J]. 中国临床药理学杂志, 2024, 40(17): 2459-2463. [Zhou X, Lou LL, Yang  L, et al. Clinical trial of salmeterol and fluticasone propionate combined with tiotropium in treatment of elderly patients with stable COPD[J]. The Chinese Journal of Clinical Pharmacology, 2024, 40(17): 2459-2463.] DOI: 10.13699/j.cnki.1001-6821. 2024.17.001.

23.徐祎琳, 刘琼, 王观林, 等. 奥马环素对社区获得性肺炎患者的疗效及安全性观察[J]. 中国感染于化疗杂志, 2024, 24(6): 638-644. [Xu WL, Liu Q, Wang GL, et al. Clinical evaluation of efficacy and safety of omadacycline in the treatment of patients with community acquired pneumonia[J]. Chinese Journal of Infection and Chemotherapy, 2024, 24(6): 638-644.] DOI: 10.16718/j.1009-7708.2024.06.002.